# Testosterone in women: what the studies included · PepVault

Source: https://pepvault.app/guides/testosterone-in-women

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [Hormones and blood tests](https://pepvault.app/guides#hormones)

# Testosterone in women: what the studies included

Reviewed November 2026 27 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Who the testosterone trials in women enrolled: menopause type, ages, estrogen use and dose, what each found, and where it is approved. Every trial in one table.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 27
- **Questions:** 8
- **Compounds:** 1

## The short answer

The testosterone trials in women enrolled mostly postmenopausal women under 70 whose low sexual desire distressed them, many after both ovaries were removed and already on estrogen. At doses that keep levels in the premenopausal range, testosterone added about one satisfying sexual event a month over placebo, with somewhat more acne and hair growth. No product is FDA-approved for women.

Every number checked at its primary source · Nov 20, 2026 · [27 sources](https://pepvault.app/guides/testosterone-in-women#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Large randomized trials of the testosterone patch in postmenopausal women (447 to 814 women each, 24 to 52 weeks), a meta-analysis of 36 trials, and few or small trials before menopause; safety data stop at 24 months.

## Which women were in the testosterone trials?

Women make testosterone too, about half of it in the ovaries before menopause[3](https://pepvault.app/guides/testosterone-in-women#source-3). When researchers pooled every blinded trial of testosterone in women lasting at least 12 weeks, they found 36 trials with 8,480 participants[1](https://pepvault.app/guides/testosterone-in-women#source-1). The sexual-function results came from 15 trials in 3,766 postmenopausal women and only 3 trials in 226 premenopausal women[18](https://pepvault.app/guides/testosterone-in-women#source-18). A pooled analysis like this is a meta-analysis (pepvault.app/glossary/meta-analysis).

Most trials recruited women with hypoactive sexual desire disorder, HSDD: low desire for sex that has lasted and that bothers them, with no other cause such as depression or a strained relationship[2](https://pepvault.app/guides/testosterone-in-women#source-2). Within that group, the trials split three ways: surgical menopause, meaning both ovaries removed, usually with a hysterectomy; natural menopause; and whether the women were already taking estrogen. The answer a study gives depends on which of these women it enrolled.

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's side-effect log takes acne, hair growth or any symptom you name, dated and rated by severity, so a change after starting is on record for the prescriber, not remembered.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Who did each trial enroll, and what did it find?

Most trials counted satisfying sexual events: sexual activity the woman herself rated satisfying, logged in a diary over four weeks. A crossover trial gives each woman both treatments in turn (pepvault.app/glossary/crossover-trial).

| Trial | Women | Ages | Menopause and estrogen | Trial dose | Found |
| --- | --- | --- | --- | --- | --- |
| Shifren, NEJM 2000 (crossover) | 75 | 31 to 56 | Surgical, on oral estrogen | Patch, 150 or 300 mcg a day, 12 weeks each | 300 mcg raised sexual frequency and pleasure scores; free testosterone stayed within the normal range on average[3](https://pepvault.app/guides/testosterone-in-women#source-3) |
| INTIMATE SM2 (Buster 2005) | 533 | 20 to 70 eligible | Surgical, on estrogen | Patch, 300 mcg a day, 24 weeks | 1.56 vs 0.73 more satisfying events per 4 weeks[4](https://pepvault.app/guides/testosterone-in-women#source-4) [10](https://pepvault.app/guides/testosterone-in-women#source-10) |
| INTIMATE SM1 (Simon 2005) | 562 | 26 to 70 | Surgical, on estrogen | Patch, 300 mcg a day, 24 weeks | 2.10 vs 0.98 more per 4 weeks[5](https://pepvault.app/guides/testosterone-in-women#source-5) |
| Braunstein 2005 (dose-finding) | 447 | 24 to 70 | Surgical, on oral estrogen | Patch, 150, 300 or 450 mcg a day | Only 300 mcg beat placebo[6](https://pepvault.app/guides/testosterone-in-women#source-6) |
| INTIMATE NM1 (Shifren 2006) | 549 | 40 to 70 eligible | Natural, on oral estrogen | Patch, 300 mcg a day, 24 weeks | 2.1 vs 0.5 more per 4 weeks[7](https://pepvault.app/guides/testosterone-in-women#source-7) [11](https://pepvault.app/guides/testosterone-in-women#source-11) |
| APHRODITE (Davis 2008) | 814 | 20 to 70 surgical, 40 to 70 natural (eligible) | Surgical or natural, no estrogen | Patch, 150 or 300 mcg a day, 52 weeks | 300 mcg: 2.1 vs 0.7 more per 4 weeks; 150 mcg not significant[8](https://pepvault.app/guides/testosterone-in-women#source-8) [9](https://pepvault.app/guides/testosterone-in-women#source-9) |
| BLOOM-1 and BLOOM-2 (LibiGel) | 597 and 575 | 30 to 65 eligible | Surgical | Gel, 300 mcg a day, 24 weeks | No benefit over placebo; published only as abstracts[12](https://pepvault.app/guides/testosterone-in-women#source-12) [26](https://pepvault.app/guides/testosterone-in-women#source-26) [18](https://pepvault.app/guides/testosterone-in-women#source-18) |
| Davis, Ann Intern Med 2008 | 261 | 35 to 46 | Premenopausal, low free testosterone | Spray: one 56 µL, one 90 µL or two 90 µL sprays a day, 16 weeks | Only the one 90 µL spray beat placebo: 2.48 vs 1.70 events per 28 days[14](https://pepvault.app/guides/testosterone-in-women#source-14) |
| El-Hage 2007 (AndroFeme cream, crossover) | 36 | Average 54 | Hysterectomy, on estrogen patches | Cream, 10 mg a day, 12 weeks | Sexual function score up 8.8 points, 44%[15](https://pepvault.app/guides/testosterone-in-women#source-15) [17](https://pepvault.app/guides/testosterone-in-women#source-17) |

Doses are what each trial gave, told as that, not a dose for anyone. A patch delivers micrograms a day; a cream or gel is measured in milligrams applied, of which only part is absorbed.

Read down the found column and two things stand out. One dose, the 300 mcg patch, carried most of the evidence, in women with and without estrogen. And placebo helped a lot: women on placebo also had more satisfying events in every patch trial[4](https://pepvault.app/guides/testosterone-in-women#source-4) [5](https://pepvault.app/guides/testosterone-in-women#source-5) [7](https://pepvault.app/guides/testosterone-in-women#source-7) [8](https://pepvault.app/guides/testosterone-in-women#source-8). The 2025 review for Australia's medicines subsidy committee noted that the two LibiGel trials, which found no benefit, sit outside the main meta-analysis because they were published only in abstract[18](https://pepvault.app/guides/testosterone-in-women#source-18).

## How much did testosterone change sex drive?

Pooled across the postmenopausal trials, testosterone added 0.85 satisfying sexual events a month over placebo or a comparator, raised desire, arousal, orgasm and pleasure, and lowered distress about sex[1](https://pepvault.app/guides/testosterone-in-women#source-1). Desire moved by a standardized mean difference of 0.36, which puts different questionnaires on one scale: 0.2 is small and 0.5 moderate. The 2019 Global Consensus Position Statement, endorsed by eleven societies, rounds this to one event a month and gives it its top evidence grade[2](https://pepvault.app/guides/testosterone-in-women#source-2).

What it did not change matters as much. The same pooled data showed no effect on general wellbeing, mood, cognition, bone density, lean mass or strength, though few women contributed to those outcomes, and a small rise in weight[1](https://pepvault.app/guides/testosterone-in-women#source-1) [2](https://pepvault.app/guides/testosterone-in-women#source-2). The statement concludes that the only evidence-based use is postmenopausal women diagnosed with HSDD after a full assessment[2](https://pepvault.app/guides/testosterone-in-women#source-2).

**Commonly reported:** a slow start, with any change in desire showing after four to eight weeks[17](https://pepvault.app/guides/testosterone-in-women#source-17); oilier skin or a few spots; finer hairs thickening where the cream goes on; for some women, little felt at all by month three.

## With this guide

### PT-141

- [PT-141: the full reference](https://pepvault.app/peptides/pt-141)
- [PT-141 dose guide](https://pepvault.app/lab/dosage/pt-141)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pt-141-10mg)

### Studies

- [PT-141: side-effect dropouts far higher than placebo in re-analysis](https://pepvault.app/research/pt-141-spielmans-2021)
- [PT-141: desire gains over placebo held across RECONNECT subgroups](https://pepvault.app/research/pt-141-reconnect-2022)
- [PT-141: more responders than placebo at 1.75 mg on all 7 measures](https://pepvault.app/research/pt-141-althof-2019)
- [All 6 studies](https://pepvault.app/research#pt-141)

### Compared with

- [PT-141 vs Melanotan II](https://pepvault.app/peptides/compare/pt-141-vs-melanotan-ii)
- [PT-141 vs Oxytocin](https://pepvault.app/peptides/compare/pt-141-vs-oxytocin)
- [PT-141 vs Setmelanotide](https://pepvault.app/peptides/compare/pt-141-vs-setmelanotide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Hormones and blood tests path

- [Raising testosterone: TRT vs enclomiphene vs hCG vs kisspeptin](https://pepvault.app/guides/raising-testosterone-trt-vs-others)
- [Enclomiphene vs clomiphene vs TRT: what the trials measured](https://pepvault.app/guides/enclomiphene-clomiphene-trt)
- [hCG vs hMG vs enclomiphene: what each one is and does](https://pepvault.app/guides/hcg-vs-hmg-vs-enclomiphene)
- [When to move up or stay on a hCG dose](https://pepvault.app/guides/hcg-dose-when-to-move-up)
- [ApoB and Lp(a) blood tests: ranges, what they mean and what lowers them](https://pepvault.app/guides/apob-and-lpa-blood-tests)
- [Biological age tests: what an epigenetic clock measures](https://pepvault.app/guides/biological-age-tests)
- [Do NAD+ blood tests mean anything?](https://pepvault.app/guides/nad-blood-tests)
- [Testosterone levels by age: what the blood test numbers mean](https://pepvault.app/guides/testosterone-levels-by-age)
- [Tongkat ali and testosterone: what the trials measured](https://pepvault.app/guides/tongkat-ali-and-testosterone)
- [DHEA benefits: what the studies show](https://pepvault.app/guides/dhea-what-studies-show)
- [Menopause and perimenopause: hormone therapy, what the trials show, and where GLP-1s fit](https://pepvault.app/guides/menopause-perimenopause-and-hrt)
- [DHEA in women: what the studies included](https://pepvault.app/guides/dhea-for-women)
- [Intermittent fasting in women: what the studies included](https://pepvault.app/guides/intermittent-fasting-in-women)
- [Ferritin levels: what low and high ferritin mean](https://pepvault.app/guides/ferritin-low-and-high)
- [Insulin resistance tests: HOMA-IR, fasting insulin and the rest compared](https://pepvault.app/guides/insulin-resistance-tests)
- [HbA1c: what the number means](https://pepvault.app/guides/what-hba1c-means)
- [CGM without diabetes: what's normal, and is it worth it?](https://pepvault.app/guides/cgm-without-diabetes)
- [Cortisol belly: what it is and what it isn't](https://pepvault.app/guides/cortisol-belly)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Indication](https://pepvault.app/glossary/indication)
- [Open-label](https://pepvault.app/glossary/open-label)
- [Crossover trial](https://pepvault.app/glossary/crossover-trial)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)

## What did it do to cholesterol, skin and hair?

The route decided the cholesterol result. Testosterone taken by mouth raised LDL and lowered HDL, the protective kind; through the skin, by patch or cream, it left lipids unchanged over the trials' length[1](https://pepvault.app/guides/testosterone-in-women#source-1) [2](https://pepvault.app/guides/testosterone-in-women#source-2). Blood pressure, blood sugar and HbA1c did not rise[2](https://pepvault.app/guides/testosterone-in-women#source-2).

Skin and hair are the side effects that showed. The New Zealand data sheet for AndroFeme 1 pools the trials of products giving the same exposure:

| Side effect | Testosterone | Placebo |
| --- | --- | --- |
| Increased hair growth | 8.6% | 6.1% |
| Acne | 7.5% | 5.0% |
| Hair loss | 4.5% | 4.4% |
| Voice change | 3.7% | 3.4% |

Source for the table:[17](https://pepvault.app/guides/testosterone-in-women#source-17). The consensus statement calls the acne and hair growth mild and finds no link at these doses to hair loss, an enlarged clitoris or a deeper voice[2](https://pepvault.app/guides/testosterone-in-women#source-2). In APHRODITE, androgen effects, mostly unwanted hair, came to 30.0% on 300 mcg against 23.1% on placebo[8](https://pepvault.app/guides/testosterone-in-women#source-8).

<!--promo-->

PepVault's side-effect log takes acne, hair growth or any symptom you name, dated and rated by severity, so a change after starting is on record for the prescriber, not remembered. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-testosterone-in-women-inline&mt=8)

<!--/promo-->

**When to get help** A voice that starts to deepen, thinning hair on the scalp or a new breast lump is a reason to contact the prescriber rather than wait for the next check.

## What about the breast and the heart?

In APHRODITE, four women on testosterone were diagnosed with breast cancer against none on placebo; one diagnosis came in the first four months and one woman had symptoms before she joined[8](https://pepvault.app/guides/testosterone-in-women#source-8). In open-label follow-up of the surgical-menopause trials, 967 women had 1,092 years of patch use between them, with three breast cancers, in line with the rate expected for their age[16](https://pepvault.app/guides/testosterone-in-women#source-16). The consensus statement finds no rise in breast density and no short-term effect on breast cancer risk, and says the trials are too short to judge the long term[2](https://pepvault.app/guides/testosterone-in-women#source-2).

For the heart, the pooled trials are short, and safety data at these doses stop at 24 months[2](https://pepvault.app/guides/testosterone-in-women#source-2). BioSante ran a safety trial of LibiGel in 3,656 women aged 50 and over with at least two heart risk factors, completed in 2012; no results are posted on its registry record[13](https://pepvault.app/guides/testosterone-in-women#source-13).

## Who did the trials leave out?

- **Premenopausal women.** Three small trials, so the consensus statement makes no recommendation for them[18](https://pepvault.app/guides/testosterone-in-women#source-18) [2](https://pepvault.app/guides/testosterone-in-women#source-2). A 2026 systematic review found two randomized trials in premenopausal women against seven in postmenopausal women[24](https://pepvault.app/guides/testosterone-in-women#source-24).
- **Women at high heart risk.** The efficacy trials excluded them, and most enrolled women already on estrogen[2](https://pepvault.app/guides/testosterone-in-women#source-2).
- **Women with breast cancer in their history.** Excluded from every HSDD trial[2](https://pepvault.app/guides/testosterone-in-women#source-2).
- **Women on antidepressants.** APHRODITE excluded SSRIs; one trial of 44 women on SSRIs or SNRIs, 77% premenopausal, found more satisfying events[9](https://pepvault.app/guides/testosterone-in-women#source-9) [18](https://pepvault.app/guides/testosterone-in-women#source-18).
- **Women on oral conjugated estrogens.** In the patch trials this subgroup did not improve significantly, and the AndroFeme 1 data sheet does not recommend use with them[17](https://pepvault.app/guides/testosterone-in-women#source-17).
- **Women without distress.** Low desire that does not bother a woman is not HSDD, and Australia's subsidy committee judged that many trial women may not have met the full HSDD criteria[18](https://pepvault.app/guides/testosterone-in-women#source-18).

## Is testosterone approved for women?

| Where | Status |
| --- | --- |
| United States | No FDA-approved indication for menopausal women; the FDA called a public workshop on it for September 17, 2026[20](https://pepvault.app/guides/testosterone-in-women#source-20) |
| European Union | Intrinsa patch (300 mcg a day) authorised July 28, 2006 for HSDD after both ovaries were removed, in women on estrogen; withdrawn May 25, 2012 at the maker's request, for commercial reasons[19](https://pepvault.app/guides/testosterone-in-women#source-19) |
| Australia | AndroFeme 1 cream registered November 23, 2020 for HSDD after menopause; a public subsidy was not recommended in November 2025[18](https://pepvault.app/guides/testosterone-in-women#source-18) |
| New Zealand | AndroFeme 1 approved April 24, 2025; label starting dose 5 mg (0.5 mL) a day[17](https://pepvault.app/guides/testosterone-in-women#source-17) |
| UK and South Africa | Listed in the FDA's August 2026 notice as approving testosterone for HSDD in women; not confirmed on either regulator's own register[20](https://pepvault.app/guides/testosterone-in-women#source-20) |

In the US, prescribers use testosterone off-label (pepvault.app/glossary/off-label), and the guideline allows an approved male gel or cream, used with care at a dose suited to women[21](https://pepvault.app/guides/testosterone-in-women#source-21). Two drugs are FDA-approved for HSDD itself: flibanserin (Addyi) for women under 65, and bremelanotide (Vyleesi, PT-141) for premenopausal women[22](https://pepvault.app/guides/testosterone-in-women#source-22) [23](https://pepvault.app/guides/testosterone-in-women#source-23); see pepvault.app/peptides/pt-141 and pepvault.app/peptides/for/libido.

## Who decides, and what do the guidelines check?

The prescriber, with the woman. The guidelines set the frame: a full assessment for other causes first; a transdermal product that keeps total testosterone in the premenopausal range; no pellets or injections, which push levels above it, and no compounded products (pepvault.app/glossary/compounded), for want of efficacy and safety data[2](https://pepvault.app/guides/testosterone-in-women#source-2) [21](https://pepvault.app/guides/testosterone-in-women#source-21). A Spanish consensus published in November 2026 holds the same line and adds that use for energy, mood or wellbeing is not supported[25](https://pepvault.app/guides/testosterone-in-women#source-25).

Testosterone is not for use in pregnancy. The male products used off-label carry that on their labels: AndroGel's, for one, says it is contraindicated in pregnant women because testosterone can cause virilization of a female fetus[27](https://pepvault.app/guides/testosterone-in-women#source-27).

A blood level does not diagnose HSDD; it is a baseline for safety[21](https://pepvault.app/guides/testosterone-in-women#source-21). The consensus statement and the AndroFeme 1 label both check total testosterone before starting and 3 to 6 weeks in, then every 6 months, and stop treatment that brings no benefit by 6 months[2](https://pepvault.app/guides/testosterone-in-women#source-2) [17](https://pepvault.app/guides/testosterone-in-women#source-17). The tests to have before any hormone are in pepvault.app/guides/blood-tests-before-starting; testosterone in men is in pepvault.app/guides/raising-testosterone-trt-vs-others.

<!--promo-->

PepVault's bloodwork section keeps total and free testosterone, SHBG, LDL and HDL draw by draw. Its built-in testosterone range and "optimal" band are set for men, so type in the range printed on your own lab report and read the result against that range. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-testosterone-in-women-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Islam RM et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019. [PubMed 31353194](https://pubmed.ncbi.nlm.nih.gov/31353194/)
2. Davis SR et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019. [PubMed 31498871](https://pubmed.ncbi.nlm.nih.gov/31498871/)
3. Shifren JL et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000. [PubMed 10974131](https://pubmed.ncbi.nlm.nih.gov/10974131/)
4. Buster JE et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005. [PubMed 15863529](https://pubmed.ncbi.nlm.nih.gov/15863529/)
5. Simon J et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005. [PubMed 16014407](https://pubmed.ncbi.nlm.nih.gov/16014407/)
6. Braunstein GD et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Arch Intern Med. 2005. [PubMed 16043675](https://pubmed.ncbi.nlm.nih.gov/16043675/)
7. Shifren JL et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause. 2006. [PubMed 16932240](https://pubmed.ncbi.nlm.nih.gov/16932240/)
8. Davis SR et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008. [PubMed 18987368](https://pubmed.ncbi.nlm.nih.gov/18987368/)
9. ClinicalTrials.gov. Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido (NCT00131495), Warner Chilcott. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00131495)
10. ClinicalTrials.gov. Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido (NCT00331214), Warner Chilcott. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00331214)
11. ClinicalTrials.gov. Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women (NCT00349791), Warner Chilcott. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00349791)
12. ClinicalTrials.gov. Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women (NCT00613002), BioSante Pharmaceuticals. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00613002)
13. ClinicalTrials.gov. Safety and Efficacy of LibiGel for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women (NCT00612742), BioSante Pharmaceuticals. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00612742)
14. Davis S et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med. 2008. [PubMed 18413618](https://pubmed.ncbi.nlm.nih.gov/18413618/)
15. El-Hage G et al. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric. 2007. [PubMed 17653960](https://pubmed.ncbi.nlm.nih.gov/17653960/)
16. Nachtigall L et al. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011. [PubMed 21142609](https://pubmed.ncbi.nlm.nih.gov/21142609/)
17. Medsafe. AndroFeme 1 (testosterone) 10 mg/mL transdermal cream, New Zealand data sheet, revised August 14, 2026. [medsafe.govt.nz](https://medsafe.govt.nz/profs/Datasheet/a/AndroFeme1Crm.pdf)
18. Pharmaceutical Benefits Advisory Committee. Public Summary Document: testosterone 1% cream (AndroFeme 1), November 2025 PBAC meeting. [prod3.pbs.gov.au](https://prod3.pbs.gov.au/industry/pbac/psd/2025/11/testosterone-psd-november-2025.pdf?variant=3)
19. European Medicines Agency. Intrinsa (testosterone): withdrawn EPAR. [ema.europa.eu](https://www.ema.europa.eu/en/medicines/human/EPAR/intrinsa)
20. US Food and Drug Administration. Testosterone Use in Menopausal Women; Public Workshop; Request for Comments. Federal Register 91:53417, August 18, 2026. [federalregister.gov](https://www.federalregister.gov/documents/2026/08/18/2026-16829/testosterone-use-in-menopausal-women-public-workshop-request-for-comments)
21. Parish SJ et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021. [PubMed 33814355](https://pubmed.ncbi.nlm.nih.gov/33814355/)
22. Addyi (flibanserin) tablets, prescribing information. DailyMed. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394)
23. Vyleesi (bremelanotide) injection, prescribing information. DailyMed. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf)
24. Furlan VA et al. Testosterone therapy for female sexual dysfunction: a systematic review of the literature demonstrating outcomes in premenopausal and postmenopausal women. J Sex Med. 2026. [PubMed 42430779](https://pubmed.ncbi.nlm.nih.gov/42430779/)
25. Sánchez-Prieto M et al. GESS-AEEM consensus on testosterone therapy in women: a clinical implementation framework. Climacteric. 2026. [PubMed 43056697](https://pubmed.ncbi.nlm.nih.gov/43056697/)
26. ClinicalTrials.gov. Safety and Efficacy of LibiGel for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women (NCT00657501), BioSante Pharmaceuticals. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00657501)
27. AbbVie. AndroGel 1.62% (testosterone gel), prescribing information, sections 4 and 8.1. DailyMed. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4e8d29b-8707-4d47-e053-2a95a90aecee)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · Hormones and blood tests

Guide · Hormones and blood tests

### [Intermittent fasting in women: what the studies included](https://pepvault.app/guides/intermittent-fasting-in-women)

Intermittent fasting in women: who the main trials enrolled (share of women, ages, menopause) and what they found for weight, DHEA, estradiol and the cycle.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [PT-141 Studied range: 0.5–2 mg](https://pepvault.app/peptides/pt-141)

## Related guides

- Guide · Hormones and blood tests

  ### [Raising testosterone: TRT vs enclomiphene vs hCG vs kisspeptin](https://pepvault.app/guides/raising-testosterone-trt-vs-others)

  TRT, enclomiphene, hCG and kisspeptin compared: what each does to LH, testosterone and sperm, what the trials measured, and which are approved.

  Read the guide
- Guide · GLP-1s

  ### [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)

  GLP-1s in menopause: tirzepatide weight loss by menopause stage, semaglutide with hormone therapy, the pill, bone and fractures, and the hot-flash trials.

  Read the guide
- Guide · Hormones and blood tests

  ### [DHEA in women: what the studies included](https://pepvault.app/guides/dhea-for-women)

  Who the DHEA trials enrolled: older women, adrenal insufficiency, IVF poor responders and menopause. Each trial's women, ages, dose and result in one table.

  Read the guide
- Guide · Getting started

  ### [Blood tests before starting a GLP-1 or a peptide, and which to repeat](https://pepvault.app/guides/blood-tests-before-starting)

  What the FDA labels for Ozempic, Wegovy, Mounjaro, Zepbound, tesamorelin, growth hormone and testosterone test before the first dose and which they repeat.

  Read the guide
- Guide · The science

  ### [How to read a peptide study](https://pepvault.app/guides/how-to-read-a-peptide-study)

  How to read a peptide study in ten minutes: the species, how many people, the placebo group, the registered outcome, and what "significant" really means.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### PT-141

- [PT-141: the full reference](https://pepvault.app/peptides/pt-141)
- [PT-141 dose guide](https://pepvault.app/lab/dosage/pt-141)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pt-141-10mg)

### Studies

- [PT-141: side-effect dropouts far higher than placebo in re-analysis](https://pepvault.app/research/pt-141-spielmans-2021)
- [PT-141: desire gains over placebo held across RECONNECT subgroups](https://pepvault.app/research/pt-141-reconnect-2022)
- [PT-141: more responders than placebo at 1.75 mg on all 7 measures](https://pepvault.app/research/pt-141-althof-2019)
- [All 6 studies](https://pepvault.app/research#pt-141)

### Compared with

- [PT-141 vs Melanotan II](https://pepvault.app/peptides/compare/pt-141-vs-melanotan-ii)
- [PT-141 vs Oxytocin](https://pepvault.app/peptides/compare/pt-141-vs-oxytocin)
- [PT-141 vs Setmelanotide](https://pepvault.app/peptides/compare/pt-141-vs-setmelanotide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Hormones and blood tests path

- [Raising testosterone: TRT vs enclomiphene vs hCG vs kisspeptin](https://pepvault.app/guides/raising-testosterone-trt-vs-others)
- [Enclomiphene vs clomiphene vs TRT: what the trials measured](https://pepvault.app/guides/enclomiphene-clomiphene-trt)
- [hCG vs hMG vs enclomiphene: what each one is and does](https://pepvault.app/guides/hcg-vs-hmg-vs-enclomiphene)
- [When to move up or stay on a hCG dose](https://pepvault.app/guides/hcg-dose-when-to-move-up)
- [ApoB and Lp(a) blood tests: ranges, what they mean and what lowers them](https://pepvault.app/guides/apob-and-lpa-blood-tests)
- [Biological age tests: what an epigenetic clock measures](https://pepvault.app/guides/biological-age-tests)
- [Do NAD+ blood tests mean anything?](https://pepvault.app/guides/nad-blood-tests)
- [Testosterone levels by age: what the blood test numbers mean](https://pepvault.app/guides/testosterone-levels-by-age)
- [Tongkat ali and testosterone: what the trials measured](https://pepvault.app/guides/tongkat-ali-and-testosterone)
- [DHEA benefits: what the studies show](https://pepvault.app/guides/dhea-what-studies-show)
- [Menopause and perimenopause: hormone therapy, what the trials show, and where GLP-1s fit](https://pepvault.app/guides/menopause-perimenopause-and-hrt)
- [DHEA in women: what the studies included](https://pepvault.app/guides/dhea-for-women)
- [Intermittent fasting in women: what the studies included](https://pepvault.app/guides/intermittent-fasting-in-women)
- [Ferritin levels: what low and high ferritin mean](https://pepvault.app/guides/ferritin-low-and-high)
- [Insulin resistance tests: HOMA-IR, fasting insulin and the rest compared](https://pepvault.app/guides/insulin-resistance-tests)
- [HbA1c: what the number means](https://pepvault.app/guides/what-hba1c-means)
- [CGM without diabetes: what's normal, and is it worth it?](https://pepvault.app/guides/cgm-without-diabetes)
- [Cortisol belly: what it is and what it isn't](https://pepvault.app/guides/cortisol-belly)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Indication](https://pepvault.app/glossary/indication)
- [Open-label](https://pepvault.app/glossary/open-label)
- [Crossover trial](https://pepvault.app/glossary/crossover-trial)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
